Buradasınız

Anasayfa » Content

DESIGN AND DEVELOPMENT OF FLOATING PULSATILE DRUG DELIVERY SYSTEM USING MELOXICAM

Journal Name:

  • The International Journal of Pharmaceutical Research and Bio-Science

Publication Year:

  • 2012

Key Words:

Author Name
Abstract (2. Language): 
The main objective of the present study was to develop single-unit floating-pulsatile drug delivery system for obtaining no drug release during floating and in the proximal small intestine followed by pulsed drug release in distal small intestine to achieve chronotherapeutic release of meloxicame for treatment of rheumatoid arthritis, osteoarthritis, spondylytis and to improve the patient compliance. The objective of present investigation was to prepare and evaluate a floating pulsatile drug delivery system of Meloxicam. The prepared floating pulsatile delivery system consisted of three different parts: a core tablet, containing the active ingredient, an erodible outer shell and a top cover buoyant layer. The rapid release core tablet (RRCT) was prepared by using superdisintegrants along with active ingredient. Dry coating of optimized RRCT was done by using different grades of hydroxyl propyl methyl cellulose (HPMC) E5, E15, and E50 and upper most buoyant layer was prepared with HPMC K15M and sodium bicarbonate. Developed formulations were evaluated for their physical characteristics, drug content, in vitro disintegration time, in vitro drug release profile (lag time), floating lag time, floating time . On the basis of these evaluation parameters it was found that optimized floating pulsatile release formulation (FPRT) F8 showed floating lag time of 4 min, floating time of 12 hrs and release lag time of 6 hrs. The F8 formulation showed compliance with chronotherapeutic objective of rheumatoid arthritis.
Bookmark/Search this post with
FULL TEXT (PDF): 
PDF icon arastirmax-design-and-development-floating-pulsatile-drug-delivery-system-using-meloxicam.pdf
  • 2
  • English

REFERENCES

References: 

1. Groning R
and Heun G: Dosage forms with controlled gastrointestinal passage -studies on the absorption of nitrofurantion. Int J Pharm 1989; 56: 111-6.
2.
Clar
k TJ: Diurnal Rhythm of Asthma. Chest 1987; 91: 137S-41.
3. Karras DJ,
D'Alonz
o GE and Heilpern KL: Is Circadian Variation in Asthma Severity Relevant in the Emergency Department. Ann Emerg Med 1995; 26:
558-62
4. Pickering TG and James GD: Determinants and consequences of the diurnal rhythm of blood pressure. Am J
Hypertens 1993; 6: 166S-9S.
5. Massin
MM
, Maeyns K, Withofs N, Ravet F and Gérard P: Circadian rhythm of heart rate and heart rate variability. Arch Dis
Child 2000; 83: 179-2.
6.
Qureshi J, Amir
M
, Ahuja A, Baboota S and Ali J: Chronomodulated Drug Delivery System of Salbutamol Sulphate for the Treatment of Nocturnal Asthma. Indian J
Pharm Sci 2008; 70: 351-6.
7.
Saito
h T, Watanabe Y, Kubo Y, Shinagawa M, Otsuka K and Ohkawa SI: Intragastric acidity and circadian rhythm. Biomed Pharmacotherapy 2001; 55: 138-41.
8.
Moor
e JG and Englert E: Circadian rhythm of gastric acid secretion in man. Nature 1970; 226: 1261-2.
9.
Ro
y P and Shahiwala A: Statistical optimization of ranitidine HCl floating pulsatile delivery system for chronotherapy of nocturnal acid breakthrough. Eur J Pharm
Sci 2009; 37: 363-9.
10. Survase S and Kumar N: Pulsatile Drug Delivery: Current Scenario. Curr Res Infor
Pharm Sci 2007; 8: 27-3.
11.
Va
n Veen MM, Sandra Kooij JJ, Marije Boonstra A, Gordijn MC and Van Someren EJ: Delayed circadian rhythm in adults with attention-deficit/hyperactivity disorder and chronic sleep-onset insomnia. Biol Psychiatry 2010; 67: 1091-6.
12. Shivkumar HG, Gwda DO and Kumar Pramod TM: Floating Controlled Drug Delivery Systems For Prolong Gastric Residence. Indian J Pharm Educ 2004; 38:
172-9.
13. Krögel
I
and Bodmeier R: Floating or pulsatile drug delivery systems based on coated effervescent cores. Int J Pharm 1999;
187: 175-4.
14.
L
i S, Lin S, Daggy B P, Mirchandani H L and Chien Y W: Effect of HPMC and Carbopol on the release and floating properties of Gastric Floating Drug Delivery System using factorial design. Int J Pharm
2003; 253: 13-22.
15. Karavas E, Georgarakis E and Bikiaris D: Application of PVP/HPMC miscible blends with enhanced mucoadhesive
properties for adjusting drug release in predictable pulsatile chronotherapeutics. Eur J Pharm Biopharm 2006; 64:115-6.
16. International Conferences on Harmonization. Stability testing of new Drug Substances and Products. Q 1 A (R2). 2003 [cited 2009 Sept 10]; Available from http://www.emea.europa.eu
17. RC Rowe, P Sheskey and P Weller: Handbook of Pharmaceutical Excipients, 4th Edition, Pharmaceutical Press Publishers, Great Britain, 2005; pp. 139-146
Available Online

Thank you for copying data from http://www.arastirmax.com